Image-Guided Surgery In The Treatment Of Rectal Cancer (AR_CRC)
Launched by IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA · Jan 28, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called AR_CRC, is exploring a new way to help surgeons perform surgery on patients with rectal cancer using advanced technology. The goal is to use special tools that provide "augmented reality" (AR) guidance during surgery. This means that before the surgery, 3D models of a patient's anatomy are created, and during the operation, these models are overlaid onto the surgeon's view to help them see important structures, like nerves and blood vessels, more clearly. This technology aims to make the surgery safer and improve outcomes by reducing complications and the chances of cancer coming back.
To be eligible for this trial, participants should be at least 18 years old and need surgery for primary rectal cancer. The trial is looking for patients who require specific types of surgery, like rectal resection or amputation. However, those who have had previous rectal surgery or have other related health issues may not qualify. Participants can expect to be part of a study that uses cutting-edge technology during their surgery, and the trial is currently recruiting individuals to take part. Overall, this research aims to enhance surgical safety and improve the experience for patients undergoing surgery for rectal cancer.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Indication for radical transabdominal surgery for primary rectal cancer
- • Resection and anastomosis or abdominal-perineal amputation surgery
- • Signature of informed consent
- • Patient's age ≥18 years.
- • CT images acquired in the arterial venous and urographic phase with section thickness:1.25/2.5 mm, level range:0.8/0.2 mm.
- • Pelvic MRI images acquired with section thickness of 1.5 mm or images acquired with 3 tesla MRI.
- Exclusion Criteria:
- • Patients who have already undergone previous rectal surgery
- • Relapse of previous rectal neoplasm
- • Neoplasm located in other pelvic organs, infiltrating the rectum
- • Indication for endoscopic or transanal treatment
- • Disease with peritoneal localisation (carcinosis)
- • Surgery for palliative purposes
- • Imaging performed elsewhere
About Irccs Azienda Ospedaliero Universitaria Di Bologna
IRCCS Azienda Ospedaliero-Universitaria di Bologna is a prestigious research and healthcare institution in Italy, renowned for its commitment to advancing medical science and patient care through innovative clinical research. As an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), it integrates clinical practice with scientific research, facilitating the translation of laboratory findings into effective treatment strategies. The institution fosters a multidisciplinary approach, collaborating with various experts to conduct high-quality clinical trials aimed at improving health outcomes across a wide range of medical fields. With a strong emphasis on ethical standards and patient welfare, IRCCS Azienda Ospedaliero-Universitaria di Bologna plays a vital role in shaping the future of medicine through rigorous scientific inquiry and patient-centered care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bologna, , Italy
Patients applied
Trial Officials
matteo rottoli, MD
Principal Investigator
IRCCS Azienda Osperaliero-Universitaria di Bologna
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported